FDA Recalls Brilliant Blue G After Eye Infection Reports

Law360, New York (March 19, 2012, 7:44 PM EDT) -- The U.S. Food and Drug Administration announced a recall of the drug Brilliant Blue G on Monday, after receiving reports of eye infections in patients who were given it during eye surgeries.

Clinicians in several states reported the infections. The FDA, the Centers for Disease Control and Prevention, and local and state public health agencies are actively investigating the incidents.

The Brilliant Blue G was supplied by Franck’s Compounding Lab in Ocala, Fla. Brilliant Blue G is not an approved drug in the United States....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.